Prescribed List: Changes from 1 November 2016

Information about the publication of Ministerial Decisions

A formal published “Ministerial Decision” is required as a record of the decision of a Minister (or an Assistant Minister where they have delegated authority) as they exercise their responsibilities and powers.

Ministers are elected by the States Assembly and have legal responsibilities and powers as “corporation sole” under the States of Jersey Law 2005 by virtue of their office and in their areas of responsibility, including entering into agreements, and under any legislation conferring on them powers.

An accurate record of “Ministerial Decisions” is vital to effective governance, including:

demonstrating that good governance, and clear lines of accountability and authority, are in place around decisions-making – including the reasons and basis on which a decision is made, and the action required to implement a decision
providing a record of decisions and actions that will be available for examination by States Members, and Panels and Committees of the States Assembly; the public, organisations, and the media; and as a historical record and point of reference for the conduct of public affairs

Ministers are individually accountable to the States Assembly, including for the actions of the departments and agencies which discharge their responsibilities.

The Freedom of Information Law (Jersey) Law 2011 is used as a guide when determining what information is be published. While there is a presumption toward publication to support of transparency and accountability, detailed information may not be published if, for example, it would constitute a breach of data protection, or disclosure would prejudice commercial interest.

A decision made 7 October 2016:

Decision Reference: MD-S-2016-0071
Decision Summary Title :	Prescribed List as of 1 November 2016		Date of Decision Summary:	4 October 2016
Decision Summary Author:	Prescribing Advisor		Decision Summary: Public or Exempt?	Public
Type of Report: Oral or Written?	Written		Person Giving Oral Report:	N/A
Written Report Title :	WR_PBAC Report 20 Sept 2016		Date of Written Report:	4 October 2016
Written Report Author:	Prescribing Advisor		Written Report : Public or Exempt?	Public
Subject: Changes to be made to the Prescribed List (Jersey) as at 1 November 2016
Decision(s): Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List. The Minister approved the following additions to the list Aveeno cream, Aveeno bath additive Cetraban cream Epaderm cream Emollin aerosol White soft paraffin Clobazam tablets 10mg for epilepsy Measles, Mumps and Rubella (MMR) vaccine for ‘catch up’ vaccination in primary care Testosterone gel 50mg/5g sachet for hormone replacement Coal tar solution 5% for psoriasis and atopic eczema Levetiracetam injection 500mg/5mL for symptom control in palliative care Tafluprost/timolol 15mcg/5mg eye drops per mL for the treatment of glaucoma Brinzolamide/brimonidine 10mcg/2mg per mL eye drops for glaucoma Brinzolamide/timolol 10mg/5mg per mL eye drops for glaucoma Dexamethasone/tobramycin 1mg/3mg per mL for post-surgical treatment of eye inflammation and infection Sacubitril with valsartan tablets (24mg/26mg, 49mg/51mg, 97mg, 103mg) for the treatment of selected patients with chronic heart failure in accordance with guidance published by NICE Azelaic acid cream 20% (Skinoren brand) for the treatment of acne Bimatoprost preservative free eye drops 300mcg/mL Timolol 1mg/g eye gel 0.4g (Tiopex brand) for the treatment of glaucoma The Minister also approved the removal of all products for the treatment of tuberculosis, these being Rifampicin/isoniazid/pyrazinamide tablets Rifampicin/isoniazid tablets, and Ethambutol tablets The Committee reiterated its support for the removal of products containing omega-3 acid ethyl esters, these being Omacor brand 1g, and generic eicosapentaenoic acid/docosahexaenoic acid capsules 1g The Minister also approved the recommendation to remove the ‘Generic only’ entry for salmeterol/fluticasone metered-dose inhaler Additions to the Prescribed List will be effective from 1 November 2016. Where items are to be removed from the List, this will be effective from 1 January 2017 and prescriptions for these products will be reimbursed until that date.
Reason(s) for Decision: The Pharmaceutical Benefit Advisory Committee (PBAC) met on 7 June and 20 September 2016 and has provided the Minister with a written report setting out its recommendations in respect of amendments to the Prescribed List. The changes reflect current evidence and expert advice, and ensure that patients in Jersey have access to an appropriate range of modern, safe and effective treatments from their GPs at a proportionate cost to the Fund.
Resource Implications: The overall financial impact of the additions to the Prescribed List was considered to be around £30,000 pa, largely due to the recommendation for sacubitril with valsartan. Anticipated growth in the use of this product will increase the cost impact of this product to around £125,000 pa by 2020/21.
Action required: Policy Principal to issue public notice listing amendments and notify all approved medical practitioners and approved contractors.
Signature:		Position: Minister
Date Signed:		Date of Decision (If different from Date Signed):